Press release
Potential Analysis of Ebola drug and Vaccines Market is Expected to Reach $56 million, Globally, by 2020
The new report by Allied Market Research titled, "Potential Analysis of Ebola drug and Vaccines Market - Global Opportunity Analysis and Industry Forecast to 2020" anticipates that the Ebola Virus Disease (EVD) vaccines would gain a market value of $56 million by 2020. The rampant growth of the disease in the under developed economics and increasing awareness among people about life threatening EVD disease has motivated healthcare authorities to introduce novel therapeutics.Read more details @ https://www.alliedmarketresearch.com/ebola-therapeutics-vaccines-market
Ebola, an orphan disease, has affected more than 20,000 people in the African countries as of now. Recurring outbreaks of Ebola in under developed region and lack of effective therapies are factors that drive the need for Ebola drugs and vaccines. The perennial outbreak of Ebola has given rise to a renewed interest among healthcare authorities in finding effective therapies. To control the EVD, the government authorities are supplying funds to pharmaceutical companies for research and development of EVD drugs and vaccines. As an example, the government of the United States, through the FDA, has granted Fast Track designation to the Tekmiras TKM Ebola drug and has funded $140 million through the Department of defense, United States, for R&D on EVD. According to AMR analyst, Roshan Deshmukh, The prime focus of the companies is to commercialize the drugs and vaccines for EVD disease. The government authorities across the developed regions are extending support for the commercialization of these drugs by providing funds and floating favorable policies.
Normal symptoms such as simple viral fever are initially observed in patients infected with EVDs; however, at later stages, the consequences of these symptoms become deadly and leave no space for recovery. In United States, EVD is termed as Quarantine able Communicable Diseases under section 361 (b) of the Public Health Service Act. This report tracks such key regulatory road maps and anticipated regulations in future by respective administrations. The report also focuses on the grass root ethical implications faced by players during clinical trials and other commercial activities.
Request Sample Report: https://www.alliedmarketresearch.com/request-free-sample/503
Allied Market Research is a Market Research Company which offers Syndicate & Custom Market Research Reports with Consulting Services.
5933 NE Win Sivers Drive,
#205, Portland, OR 97220,
United States.
Int'l: +1-503-894-6022
Toll Free: +1-800-792-5285
Fax: +1-800-792-5285
help@alliedmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Potential Analysis of Ebola drug and Vaccines Market is Expected to Reach $56 million, Globally, by 2020 here
News-ID: 494214 • Views: …
More Releases from Allied Market Research

Global Urinary Drainage Bags Market: Trends, Growth, and Insights to 2031
The global urinary drainage bags market is experiencing robust growth, with its market size valued at $1.4billion in 2021 and projected to reach $2billion by 2031. This expansion represents a compound annual growth rate (CAGR) of 3.8% from 2021 to 2031, highlighting the increasing demand for these essential medical devices.
Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A17529
What Are Urinary Drainage Bags?
Urinary drainage bags are specialized medical devices designed to collect…

Cream Powder Market to Reach $8.9 Billion by 2031 with 6.4% CAGR
The global cream powder industry was estimated at $4.8 billion in 2021 and is expected to hit $8.9 billion by 2031, registering a CAGR of 6.4% from 2022 to 2031.
The cream powder market is experiencing growth due to various factors, including the increasing popularity of bakeries and HoReCa (hotels, restaurants, and cafes) and rising consumer demand for natural products. The dairy-based segment is a significant contributor to the market's growth…

Micro Drone Market Valued at $6.71 Billion in 2020, Expected to Reach $28.91 Bil …
The global micro drone industry generated $6.71 billion in 2020, and is expected to reach $28.91 billion in 2030, witnessing a CAGR of 17.2% from 2021 to 2030. The report provides an extensive analysis of changing market dynamics, top segments, top investment pockets, regional landscape, value chain, and competitive scenario.
Increased operational efficiency and rise in demand for improved surveillance drive the growth of the global micro drone market. However, strict…

Microwavable Foods Market to reach $230.93 billion by 2031, growing at a CAGR of …
The global microwaveable foods industry was accounted for $120.45 billion in 2020, and is expected to reach $230.93 billion by 2031, growing at a CAGR of 5.6% from 2022 to 2031.
Rise in popularity of fast-food restaurants and large population base coupled with increase in number of quick-service restaurants drive the global microwaveable foods market. However, lack of awareness about microwavable foods hinders the market growth. On the contrary, rise in…
More Releases for EVD
Impact Of Rising Ebola Virus Disease (EVD) Cases On the Ebanga Market: An Emergi …
The Ebanga Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Ebanga Market?
In recent times, the ebanga market size has experienced an XX (HCAGR). The projection suggests an increase from $XX million in 2024 to $XX million in 2025,…
What's Driving the Ebanga Market 2025-2034: Impact Of Rising Ebola Virus Disease …
What Is the Forecasted Market Size and Growth Rate for the Ebanga Market?
The size of the ebanga market has shown a progressive trend, having a HCAGR of $XX over recent years. It is projected to expand from $XX million in 2024 to an impressive $XX million come 2025, owing to a Compound Annual Growth Rate (CAGR) of $XX%. This growth during the historic period can be ascribed to multiple factors…
Intracranial Pressure Monitoring Devices Market By Device type (Subarachnoid bol …
Report Overview
The market for intracranial pressure monitoring devices was valued at USD 1.46 billion in 2021, and from 2023 to 2032, it is anticipated to increase at a compound annual growth rate (CAGR) of 6.9%. The market is expected to increase due to the rise in neurological illnesses, the ageing population in Asia Pacific, particularly in nations like China, Japan, and India, and rapid technological advancements. On the market, the…
Ebola Vaccine Market Detailed Analysis and Forecast 2018-2026 | Merck, Janssen P …
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus…
Ebola Vaccine Market Analysis By Key Players Merck and Company, Janssen Pharmace …
In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells.
Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/1365
According to study published in…
Ebola Vaccine Market in Depth Analysis2026 | Top Key Players Merck and Company, …
In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells.
According to study published in the journal, The Lancet,…